Zometa in therapy for bone metastases of prostate cancer during androgenic deprivation (Results of Russian multicenter study)

O. B. Karyakin; Карякин О. Б.; B. P. Matveev; Матвеев Б. П.; V. B. Matveev; Матвеев В. Б.; I. G. Rusakov; Русаков И. Г.; O. B. Loran; Лоран О. Б.; Ye. I. Veliyev; Велиев Е. И.; L. V. Shaplygin; Шаплыгин Л. В.; B. V. Bukharkin; Бухаркин Б. В.; V. A. Biryukov; Бирюков В. А.; N. G. Minayeva; Минаева Н. Г.; A. A. Atayev; Атаев А. А.; V. M. Shelepova; Шелепова В. М.; M. I. Karelin; Карелин М. И.; D. G. Prokhorov; Прохоров Д. Г.; Yu. N. Khrizman; Хризман Ю. Н.; V. K. Shakurov; Шакуров В. К.; E. F. Abdrakhmanov; Абдрахманов Э. Ф.; V. N. Zhuravlev; Журавлев В. Н.; A. V. Zyryanov; Зырянов А. В.; V. O. Mager; Магер В. О.; P. A. Karnaukh; Карнаух П. А.

doi:10.17650/1726-9776-2007-0-2-56-60

Zometa in therapy for bone metastases of prostate cancer during androgenic deprivation (Results of Russian multicenter study)

Authors: Karyakin O.B.¹, Matveev B.P.², Matveev V.B.², Rusakov I.G.³, Loran O.B.⁴, Veliyev Y.I.⁵, Shaplygin L.V.⁶, Bukharkin B.V.², Biryukov V.A.¹, Minayeva N.G.¹, Atayev A.A.², Shelepova V.M.², Karelin M.I.⁷, Prokhorov D.G.⁷, Khrizman Y.N.⁸, Shakurov V.K.⁸, Abdrakhmanov E.F.⁹, Zhuravlev V.N.¹⁰, Zyryanov A.V.¹¹, Mager V.O.¹², Karnaukh P.A.¹³
Affiliations:
1. Medical Radiology Research Center, Russian Academy of Medical Sciences
2. N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
3. P.A. Herzen Moscow Research Oncological Institute, Ministry of Health and Social Development of the Russian Federation
4. Department of Urology and Surgical Andrology, Russian Medicаl Academy of Postgraduate Education
5. Department of Urology and Surgical Andrology, Russian Medicаl Academy of Postgraduate Education
6. N.N. Burdenko Main Military Clinical Hospital
7. Central Research Institute of Radiology, Ministry of Health and Social Development of the Russian Federation
8. Bashkir Republican Cancer Dispensary
9. Kazan Cancer Dispensary
10. Department of Urology, Urals State Medical Academy
11. Cancer Clinical Hospital No.1
12. Sverdlovsk Regional Cancer Dispensary
13. Regional Cancer Dispensary
Issue: Vol 3, No 2 (2007)
Pages: 56-60
Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
Published: 30.06.2007
URL: https://oncourology.abvpress.ru/oncur/article/view/1264
DOI: https://doi.org/10.17650/1726-9776-2007-0-2-56-60
ID: 1264

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Introduction: Hormonal therapy is the method of choice in treating disseminated prostate cancer. Chronic androgenic suppression causes a reduction in bone mineral density. The most common complications of bone metastases are pathological fractures, spinal cord compression, pain, etc.

Methods: A multicenter study (11 clinics of Russia) assessing the efficacy of Zometa in preventing skeletal complications of bone metastases was conducted in 2004—2005. Zometa was administered intravenously at a dose of 4 mg every 3Р4 weeks with androgenic deprivation. Its objective effect was evaluated in 70 patients. Changes in bone mineral density were evaluated by densitometry.

Results: Complete pain relief was achieved in 73% of the patients; after therapy 86% of the patients had 0—1 WHO activity status score, 97% of the patients had no bone complications. The level of bone resorption marker β-Cross-Laps decreased to the normal values in 51% of the patients.

Conclusion: The study has provided an evidence of the efficacy of Zometa and the necessity of using this drug in complex therapy for bone metastases of prostate cancer.

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Zometa in therapy for bone metastases of prostate cancer during androgenic deprivation (Results of Russian multicenter study)

Full Text

Abstract

About the authors

References

Supplementary files